<DOC>
	<DOCNO>NCT02017808</DOCNO>
	<brief_summary>This prospective , observational , single-blinded , longitudinal , 24-month OCT study evolution axonal loss , evidence loss RNFLT TMV , RRMS patient treat GA healthy control .</brief_summary>
	<brief_title>Studying Effects Copaxone Retinal Health Using Optical Tomography Over 24 Months</brief_title>
	<detailed_description>The primary aim study explore whether treatment Copaxone may decrease accumulation axonal loss , measure retinal nerve fiber layer thickness ( RNFLT ) optical coherence tomography ( OCT ) patient RRMS 24 month compare reference population healthy control . The secondary objective study investigate effect GA total macular volume ( TMV ) OCT patient RRMS 24 month . We also explore 24-month change RNFLT TMV OCT relate progression disability , measure Expanded Disability Status Scale ( EDSS ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>MS patient diagnose clinically definite MS accord McDonald criterion ( Polman et al. , 2005 ) Starting GA monotherapy ( 20mg/day sc ) time OCT scan Having baseline clinical OCT scan include RNFLT TMV assessment start GA Having baseline clinical OCT scan include RNFLT TMV assessment ( healthy control ) MS patient RR disease course ( Lublin Reingold , 1996 ) Age 1865 ( healthy control match MS patient age sex ) Signed informed consent 24month followup None exclusion criterion Patients relapse within 30 day prior OCT scan date Patients receive steroid treatment within 30 day prior OCT scan date Women pregnant , lactate childbearing age consent approve contraceptive use study MS patient use imunomodulatory immunosuppressant treatment GA followup ( e.g. , IFNÎ² , mitoxantrone , cyclophosphamide , cladribine , fludarabine , cyclosporine , total body , azathioprine , methotrexate , IVIG , cellcept , natalizumab , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>OCT</keyword>
	<keyword>Copaxone</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>relapsing-remitting</keyword>
</DOC>